Immunotherapy as a neoadjuvant preoperative treatment for locally advanced pulmonary sarcomatoid carcinoma: a case report of clinical efficacy
BackgroundPulmonary sarcomatoid carcinoma (PSC) is a rare subtype of non-small cell lung cancer (NSCLC) with a generally poor prognosis. Studies have shown that the survival rate for advanced-stage patients is less than 5%, with a median overall survival (OS) of less than 6.5 months.Case reportHerei...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2025.1483766/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832582935387045888 |
|---|---|
| author | Hanhan Li Hanhan Li Ruilian Chen Wei Guo Shang Xiang Shang Xiang Jiayang Huang Jiayang Huang Hanrui Chen |
| author_facet | Hanhan Li Hanhan Li Ruilian Chen Wei Guo Shang Xiang Shang Xiang Jiayang Huang Jiayang Huang Hanrui Chen |
| author_sort | Hanhan Li |
| collection | DOAJ |
| description | BackgroundPulmonary sarcomatoid carcinoma (PSC) is a rare subtype of non-small cell lung cancer (NSCLC) with a generally poor prognosis. Studies have shown that the survival rate for advanced-stage patients is less than 5%, with a median overall survival (OS) of less than 6.5 months.Case reportHerein, we report a case of locally advanced PSC in a 56-year-old male patient who received platinum-based double-drug therapy combined with anti-angiogenic drugs, followed by immunotherapy as the first-line systemic treatment. After undergoing eight cycles of neoadjuvant therapy, the opportunity for surgery arose. Postoperative pathology confirmed that the neoadjuvant chemotherapy in this regimen achieved pathological complete remission (pCR). At present, the patient maintains a good quality of life, continues with immunotherapy for consolidation and prevention of recurrence, and has reached a survival period of 10 months.ConclusionFor patients with locally advanced PSC who do not have significant genetic mutations, the use of immunotherapy as a first-line neoadjuvant and adjuvant therapy may hold promise for achieving a pCR. Further research into this treatment protocol is warranted. |
| format | Article |
| id | doaj-art-2fe60af6d839447daf3cbfc614d353a1 |
| institution | Kabale University |
| issn | 2234-943X |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-2fe60af6d839447daf3cbfc614d353a12025-01-29T05:21:10ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-01-011510.3389/fonc.2025.14837661483766Immunotherapy as a neoadjuvant preoperative treatment for locally advanced pulmonary sarcomatoid carcinoma: a case report of clinical efficacyHanhan Li0Hanhan Li1Ruilian Chen2Wei Guo3Shang Xiang4Shang Xiang5Jiayang Huang6Jiayang Huang7Hanrui Chen8The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, ChinaLingnan Medical Research Center, Guangzhou University of Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, ChinaThe First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, ChinaThe First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, ChinaThe First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, ChinaLingnan Medical Research Center, Guangzhou University of Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, ChinaThe First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, ChinaLingnan Medical Research Center, Guangzhou University of Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, ChinaThe First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, ChinaBackgroundPulmonary sarcomatoid carcinoma (PSC) is a rare subtype of non-small cell lung cancer (NSCLC) with a generally poor prognosis. Studies have shown that the survival rate for advanced-stage patients is less than 5%, with a median overall survival (OS) of less than 6.5 months.Case reportHerein, we report a case of locally advanced PSC in a 56-year-old male patient who received platinum-based double-drug therapy combined with anti-angiogenic drugs, followed by immunotherapy as the first-line systemic treatment. After undergoing eight cycles of neoadjuvant therapy, the opportunity for surgery arose. Postoperative pathology confirmed that the neoadjuvant chemotherapy in this regimen achieved pathological complete remission (pCR). At present, the patient maintains a good quality of life, continues with immunotherapy for consolidation and prevention of recurrence, and has reached a survival period of 10 months.ConclusionFor patients with locally advanced PSC who do not have significant genetic mutations, the use of immunotherapy as a first-line neoadjuvant and adjuvant therapy may hold promise for achieving a pCR. Further research into this treatment protocol is warranted.https://www.frontiersin.org/articles/10.3389/fonc.2025.1483766/fullpulmonary sarcomatoid carcinomarare lung cancer subtypetumor immunotherapyneoadjuvant treatmentpathological complete remissioncase report |
| spellingShingle | Hanhan Li Hanhan Li Ruilian Chen Wei Guo Shang Xiang Shang Xiang Jiayang Huang Jiayang Huang Hanrui Chen Immunotherapy as a neoadjuvant preoperative treatment for locally advanced pulmonary sarcomatoid carcinoma: a case report of clinical efficacy Frontiers in Oncology pulmonary sarcomatoid carcinoma rare lung cancer subtype tumor immunotherapy neoadjuvant treatment pathological complete remission case report |
| title | Immunotherapy as a neoadjuvant preoperative treatment for locally advanced pulmonary sarcomatoid carcinoma: a case report of clinical efficacy |
| title_full | Immunotherapy as a neoadjuvant preoperative treatment for locally advanced pulmonary sarcomatoid carcinoma: a case report of clinical efficacy |
| title_fullStr | Immunotherapy as a neoadjuvant preoperative treatment for locally advanced pulmonary sarcomatoid carcinoma: a case report of clinical efficacy |
| title_full_unstemmed | Immunotherapy as a neoadjuvant preoperative treatment for locally advanced pulmonary sarcomatoid carcinoma: a case report of clinical efficacy |
| title_short | Immunotherapy as a neoadjuvant preoperative treatment for locally advanced pulmonary sarcomatoid carcinoma: a case report of clinical efficacy |
| title_sort | immunotherapy as a neoadjuvant preoperative treatment for locally advanced pulmonary sarcomatoid carcinoma a case report of clinical efficacy |
| topic | pulmonary sarcomatoid carcinoma rare lung cancer subtype tumor immunotherapy neoadjuvant treatment pathological complete remission case report |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2025.1483766/full |
| work_keys_str_mv | AT hanhanli immunotherapyasaneoadjuvantpreoperativetreatmentforlocallyadvancedpulmonarysarcomatoidcarcinomaacasereportofclinicalefficacy AT hanhanli immunotherapyasaneoadjuvantpreoperativetreatmentforlocallyadvancedpulmonarysarcomatoidcarcinomaacasereportofclinicalefficacy AT ruilianchen immunotherapyasaneoadjuvantpreoperativetreatmentforlocallyadvancedpulmonarysarcomatoidcarcinomaacasereportofclinicalefficacy AT weiguo immunotherapyasaneoadjuvantpreoperativetreatmentforlocallyadvancedpulmonarysarcomatoidcarcinomaacasereportofclinicalefficacy AT shangxiang immunotherapyasaneoadjuvantpreoperativetreatmentforlocallyadvancedpulmonarysarcomatoidcarcinomaacasereportofclinicalefficacy AT shangxiang immunotherapyasaneoadjuvantpreoperativetreatmentforlocallyadvancedpulmonarysarcomatoidcarcinomaacasereportofclinicalefficacy AT jiayanghuang immunotherapyasaneoadjuvantpreoperativetreatmentforlocallyadvancedpulmonarysarcomatoidcarcinomaacasereportofclinicalefficacy AT jiayanghuang immunotherapyasaneoadjuvantpreoperativetreatmentforlocallyadvancedpulmonarysarcomatoidcarcinomaacasereportofclinicalefficacy AT hanruichen immunotherapyasaneoadjuvantpreoperativetreatmentforlocallyadvancedpulmonarysarcomatoidcarcinomaacasereportofclinicalefficacy |